Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04318145 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects
A Phase 2 study, sponsored by Palatin Technologies.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT04318145: Clinical Trial Phase 2 study, sponsored by Palatin Technologies.
NCT04318145 is a Phase 2 study that was terminated before completion, run by Palatin Technologies. The registered enrollment target is 15 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04318145, a Phase 2 study, was terminated before completion, sponsored by Palatin Technologies.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
A Multi-Center, Unblinded, Single-Arm Study to Evaluate Sex Differences in the Acute Effects of PL-3994 on Myocardial cGMP Enhancement and Hemodynamics in Heart Failure with Preserved Ejection Fraction
Primary Outcome
Reaching the maximum tolderated dose (MTD) as defined by meeting stopping criteria.
Interventions
- DRUG PL-3994 Aqueous Intravenous Solution Dose Ascention
- DRUG PL-3994 Aqueous Intravenous Solution Single Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-11-12 |
| Est. Completion | 2023-12-08 |
| Phase | Phase 2 |
Why NCT04318145 stopped before completion
NCT04318145 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which PL-3994 Aqueous Intravenous Solution Dose Ascention is the first listed.
NCT04318145 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04318145 about?
NCT04318145 is a clinical study titled "Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects". A Multi-Center, Unblinded, Single-Arm Study to Evaluate Sex Differences in the Acute Effects of PL-3994 on Myocardial cGMP Enhancement and Hemodynamics in Heart Failure with Preserved Ejection Fraction
What is the current status of trial NCT04318145?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2020-11-12. Estimated completion is 2023-12-08.
What interventions are being tested in trial NCT04318145?
The interventions under investigation include: PL-3994 Aqueous Intravenous Solution Dose Ascention (DRUG), PL-3994 Aqueous Intravenous Solution Single Dose (DRUG).
Who is sponsoring clinical trial NCT04318145?
This trial is sponsored by Palatin Technologies, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04318145's enrollment target sits among peer trials
15 1919th of 2000 higher than 60 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI